Cargando…
Systemic delivery of P42 peptide: a new weapon to fight Huntington’s disease
BACKGROUND: In Huntington’s disease (HD), the ratio between normal and mutant Huntingtin (polyQ-hHtt) is crucial in the onset and progression of the disease. As a result, addition of normal Htt was shown to improve polyQ-hHtt-induced defects. Therefore, we recently identified, within human Htt, a 23...
Autores principales: | Arribat, Yoan, Talmat-Amar, Yasmina, Paucard, Alexia, Lesport, Pierre, Bonneaud, Nathalie, Bauer, Caroline, Bec, Nicole, Parmentier, Marie-Laure, Benigno, Lorraine, Larroque, Christian, Maurel, Patrick, Maschat, Florence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149238/ https://www.ncbi.nlm.nih.gov/pubmed/25091984 http://dx.doi.org/10.1186/s40478-014-0086-x |
Ejemplares similares
-
A Huntingtin Peptide Inhibits PolyQ-Huntingtin Associated Defects
por: Arribat, Yoan, et al.
Publicado: (2013) -
Vesicular Axonal Transport is Modified In Vivo by Tau Deletion or Overexpression in Drosophila
por: Talmat-Amar, Yasmina, et al.
Publicado: (2018) -
The P42 peptide and Peptide-based therapies for Huntington’s disease
por: Marelli, Cecilia, et al.
Publicado: (2016) -
Fighting Epilepsy with Nanomedicines—Is This the Right Weapon?
por: Matias, Mariana, et al.
Publicado: (2023) -
Cyclosporine: an old weapon in the fight against coronaviruses
por: Molyvdas, Adam, et al.
Publicado: (2020)